基本信息
浏览量:32
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
个人简介
Jonathan is a physician, health economist, and health policy expert, who has a 30 year history of combining clinical understanding with expertise in medical device and drug development, health information technology, health policy, and health economics. Currently, he serves as CEO of NeuroRx, Inc., which is developing SamiVir™ (aviptadil) to treat Respiratory Failure in Critical COVID-19 and to prevent respiratory failure in moderate COVID-19. SamiVir blocks coronavirus replication, cytokine production, and cell death in human lung cells. NeuroRx is also developing NRX-101, an FDA-designated Breakthrough drug targeting suicidal depression and PTSD. He is a graduate of Princeton University, Cornell University Medical College, Harvard School of Public Health, the Wills Eye Hospital, and the Wilmer Ophthalmological Institute, of Johns Hopkins University, where he remains a member of the faculty.
Jonathan was a pioneer in the use of patient-reported outcomes and health economic research in drug and medical device development. He has served on drug and device development teams for Merck, Pharmacia, Pfizer, Bayer, Allergan, Alcon, and Eyetech, where he helped to pioneer the integration of pharmacoeconomic outcomes and patient quality of life into the drug and device clinical trials and product approvals. His experience includes regulatory expertise in FDA and CE compliance with the drug and device approval process and quality system management.
Jonathan has been a founder of 6 health informatics and analytics companies that have gone on to successful public acquisitions: Healthcare Computer Associates (NYSE: SMSI), NextGen (Nasdaq:QSII), Certitude (NYSE:UNH), Active Health Management (NYSE:UNH), First Gateways (NYSE:DGX) and Coderyte, Inc., (NYSE:3M), and Telcare, Inc., funded by Qualcomm Ventures, Sequoia Capital, and Norwest Venture Partners. Most recently, he has founded NeuroRx, Inc., a clinical stage pharmaceutical company targeting the brain’s NMDA receptor for treatment of acute suicidal crisis in patients with depression.
In the policy arena, Prof. Javitt has served as a senior health advisor to three US Presidential administrations. Most recently, he was commissioned by President Bush to chair the Health Subcommittee of the President’s Information Technology Advisory Committee (PITAC) which created the blueprint for the Office of the National Coordiator for Health IT and the HITECH act. He also served as a Special Employee of the Undersecretary of Defense. He is a Senior Fellow in the National Security Health Policy Center of the Potomac Institute for Policy Studies since September 2001. He has been responsible for projects undertaken in conjunction with the White House Homeland Security Council, the National Transportation Safety Board, the FDA, Medicare, and the Veterans Administration. He has additionally served as a delegate to the White House Conference on Aging and as a member of the White House Health Reform Task Force. He has been also served as a consultant to the World Bank, the National Institutes of Health, the Health Care Financing Administration, Department of Veterans Affairs, and the ministries of health of United Kingdom, Sweden, Australia, Japan, Israel, and the Netherlands.
Jonathan was awarded a Kellogg Foundation Fellowship in Health Management by the Harvard T.H. Chan School of Public Health in 1982 and has been granted its 2015 Alumnus of Merit award. He has served as Professor of Ophthalmology and Public Policy on the full time faculties of Georgetown and Johns Hopkins Universities and remains an adjunct Professor of Ophthalmology at Johns Hopkins. In his academic career he directed and participated in more than $100 million of federally-funded research focused on outcomes of, and delivery of, health care including diseases of the eye, diabetes, and breast cancer. He authored the first book on computers in medicine in 1984 and has published more than 200 scientific works in the New England Journal of Medicine, the Journal of the American Medical Association, and numerous other peer-reviewed publications. He is lead inventor on seven US patents. His published work has been cited by more than 24,000 people and he is in the top 1% of the most widely quoted scientists. He is listed in Who’s Who in America and Who’s Who in the World.
研究兴趣
论文共 276 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
ANTIBIOTICS-BASELno. 4 (2024)
Matthieu Jabaudon,Melissa A. Warren,Tatsuki Koyama,Philip Lavin,Jonathan C. Javitt, Melvin L. Morganroth, Marc Korczykowski, John W. Hollingsworth,Richard A. Lee,Jihad G. Youssef,Lorraine B. Ware
CHEST Critical Carepp.100081, (2024)
biorxiv(2024)
M. Jabaudon, M. Warren, T. Koyama,P. Lavin,J. Javitt, M. L. Morganroth, M. Korczykowski, R. Besthof, R. A. Lee, J. Youssef, L. B. Ware
引用0浏览0引用
0
0
Pharmacology Biochemistry and Behavior (2023): 173586-173586
Andrew Nierenberg, Philip Lavin,Daniel C. Javitt,Richard Shelton,Sanjay Matthew, Robert A Besthof,Jonathan C. Javitt
International Journal of Toxicologyno. 5 (2022): 379-385
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn